Kornimate/medical-research-clean huggingface dataset:
artificial intelligence in eus for diagnosing pancreatic solid lesions

Conditions: Pancreatic Ductal Adenocarcinoma; Pancreatitis, Chronic; Pancreatic Neuroendocrine Tumor; Autoimmune Pancreatitis

Summary: we aim to develop an eus-ai model which can facilitate clinical diagnosis by analyzing eus pictures and clinical parameters of patients.

eus is considered to be a more sensitive modality than ct in detecting pancreatic solid lesions due to its high spatial resolution. however, the diagnostic performance is largely dependent on the experience and the technical abilities of the practitioners. therefore, we aim to develop an objective eus diagnostic model based on the convolutional neural network, an artificial intelligence technique. in addition, clinical parameters such as risk factors, tumor biomarkers and radiology findings are also added to this artificial intelligence model in order to mimic the actual clinical diagnosis procedures and to increase the performance of this model.

Eligibility criteria:
inclusion criteria: * patients who underwent eus using a curved line array echoendoscope (gf-uct260; olympus medical systems) since 2014 in our affiliation. * for each patient, all available native eus pictures are included. * patients' diagnosis are validated by surgical outcomes or fine-needle aspiration (fna) findings and have a compatible clinical course with a follow-up period of more than 6 months. exclusion criteria: * the image is of poor quality. * the images contain unique marks which can potentially bias the model, such as the biopsy needle.

Keywords: artificial intelligence endoscopic ultrasound
safety trial of iressa, cisplatin and radiation therapy for patients with head and neck cancer

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to find out whether adding zd1839 to standard treatment (cisplatin and radiation therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.

this is a phase i-ii, open-label, dose-escalation study in subjects with advanced head or neck cancer. subjects will receive daily zd1839 during a course of standard radiation therapy accompanied by cisplatin. subjects are adults with stage iii-iv squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx, who are in medically stable condition, with an eastern cooperative oncology group (ecog) performance status of £ 1, stable hepatic and bone marrow function, and a life expectancy of at least 6 months. subjects should have no previous cancer history (with the exception of squamous cell carcinoma of the skin or cervical cancer in situ) and no prior treatment with radiation, chemotherapy, or definitive surgical therapy. subjects in the phase ii portion of the trial must have measurable disease as defined by recist criteria.

Eligibility criteria:
inclusion criteria: * histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx. for the phase ii portion of the study: measurable disease as based on recist criteria. * stage iii or iv disease, m0. * life expectancy \> 6 months. exclusion criteria: * known severe hypersensitivity to zd1839 or any of the excipients of this product. * other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of squamous cell carcinoma of the skin or cervical cancer in situ. * previous treatment with radiation, chemotherapy, or definitive surgical therapy. * distant metastatic disease. * documented evidence of hiv infection (because the interaction of zd1839 with highly active anti-retroviral therapy \[haart\] is unknown). * substance abuse or psychiatric problems that would interfere with compliance. * pregnancy or breast-feeding (women of child-bearing potential). * treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment. * any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)

Keywords: head and neck cancer squamous cell carcinoma of the oral cavity squamous cell carcinoma of the oropharynx squamous cell carcinoma of the larynx squamous cell carcinoma of the hypopharynx
intrapartum fever: antibiotics versus no treatment

Conditions: Chorioamnionitis; Intrapartum Fever; Intra-amniotic Infection

Summary: the purpose of this study is to determine whether antibiotics can be safely avoided in women who develop a fever during labor. because investigators have no accurate tests to determine whether women who develop fever during labor have intra-amniotic infection, antibiotics are often used to prevent spread of infection to the fetus.

a fever \> 100.4 f during labor (intrapartum fever) complicates up to 14% of term deliveries, and is commonly considered a sign of intrauterine infection. despite studies showing that most causes of maternal intrapartum fever are non-infectious, intrapartum fever often prompts the diagnosis of chorioamnionitis/intrauterine infection, or what is now known as 'triple i' (intra-amniotic infection or inflammation). diagnosis of triple i is primarily based on clinical findings such as maternal fever, maternal leukocytosis, uterine tenderness, foul-smelling or purulent amniotic fluid, and fetal tachycardia. a minimum of two of these criteria for diagnosis, although this distinction is somewhat artificial as fetal tachycardia is highly associated with maternal fever. the poor performance of clinical signs and lack of effective biomarkers to identify neonatal infection results in over treatment of both mothers and infants. avoiding antibiotic use in mothers and infants is desirable in order to avoid unnecessary separation after birth, decreasing cost and interventions in newborns, and to avoid altering the infant's microbiome (the bacteria newborns carry on their skin, mucosal membranes, and in their gut at the time of birth). infants with altered microbiomes may be at risk for skin, pulmonary, and gastrointestinal disorders. the investigators in this trial are randomizing women with fever during labor who are felt to be a low risk for true infection to antibiotic treatment compared to no antibiotics in order to determine if antibiotics can be safely avoided for these women and their infants.

Eligibility criteria:
inclusion criteria: * pregnant women between 34-42 weeks gestation * singleton fetus * admitted for labor management \& develops a fever of 100.4 f or greater exclusion criteria: * known fetal anomaly * other indication for intrapartum antibiotics (endocarditis prophylaxis, other known maternal infection)
effect of combined music and taekwondo training for children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the goal of this randomized controlled trial is to evaluate the effect of combined music and taekwondo training on the mental and physical condition of children with autism spectrum disorder. participants will be asked to do combined music and taekwondo training or taekwondo training alone to evaluate if the combined training is better than the taekwondo training alone on mental and physical performance for children with autism spectrum disorder.


Eligibility criteria:
inclusion criteria: * chinese children aged 7 to 9 years who have been clinically diagnosed as asd by developmental paediatricians or clinical psychologists based on the diagnostic and statistical manual of mental disorders, fifth edition criteria for asd. exclusion criteria: * children who have experience in taekwondo training; * children who have received music therapy within the previous 12 months; * those who have severe sensory disorders (blindness or deafness); * those who have underlying congenital abnormalities or other diseases that limit their ability to engage in physical activities.

Keywords: music taekwondo autism spectrum disorder
problem solving skills training for parent caregivers of youth with chronic pain

Conditions: Chronic Pain; Abdominal Pain; Headache

Summary: the purpose of this study is to evaluate the feasibility and efficacy of problem-solving skills training (psst) to reduce distress and increase coping abilities among parents of youth with chronic pain. we hypothesize that parents will complete the psst intervention and will find it to be an acceptable and satisfactory treatment. we also hypothesize that parents who receive psst will have less distress and better coping skills than parents who receive standard care, and that children of parents who receive psst will have better physical and emotional functioning than children of parents who receive standard care.

chronic pain affects 25-40% of children and adolescents, and results in significantly lower quality of life for these youth. parents play an important role in how their children cope with chronic pain, and can also experience their own distress related to their child's illness. parental psychological distress is widely recognized to be associated with poorer child adjustment. however, no interventions have been developed specifically to treat psychological distress in parents of children with chronic pain. problem-solving skills training (psst) has been shown to result in significant reductions in parental distress among caregivers of children with other types of chronic illness such as cancer. the purpose of this study is to test the feasibility and preliminary efficacy of psst for parents of youth with chronic pain.

Eligibility criteria:
inclusion criteria: * child age 10-17 years * child's pain present for at least 3 months duration * pain occurs at least 1 time per week and interferes with daily functioning * pain is not related to a chronic disease * receiving evaluation or treatment in a pediatric pain clinic * literate in english exclusion criteria: * a serious comorbid chronic condition in the child (e.g., diabetes, arthritis, cancer) * non-english speaking * parent has lived with the child for less than one year * parent has active psychosis or suicidal ideation

Keywords: chronic pain abdominal pain headache adolescents children parents problem-solving skills training
a study of ro5028442 in adult male high-functioning autistic patients

Conditions: Autistic Disorder

Summary: this multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of ro5028442 in adult male high-functioning autistic patients. in a cross-over design, patients will be randomized to receive either a single dose of ro5028442 or matching placebo with a washout period of 7-14 days. anticipated time on study is up to approximately 9 weeks.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of autistic disorder as defined by dsm-iv, confirmed by the team and supported with the autistic diagnostic observation schedule (ados) * male adults, 18 to 45 years of age * iq \> 70 (wechsler adult intelligence scale-full scale) * body mass index (bmi) 18 to 35 kg/m2 inclusive * aberrant behavior checklist (abc) - irritability subscale score \</= 13 exclusion criteria: * positive urine test for drugs of abuse * alcohol and/or substance abuse/dependence during the last 12 months * positive for hepatitis b, hepatitis c or hiv infection * clinically relevant cardiovascular, renal, hepatic or hematologic disease or disorder * active inflammatory pulmonary disease * history of epilepsy/seizure disorder (except for simple febrile seizures) * initiation of new or major change in psychosocial intervention within 4 weeks prior to randomization * treatment with any investigational agent within 90 days prior to screening * history of hypersensitivity or allergic reactions
paricalcitol on albuminuria, inflammation and fibrosis on proteinuric chronic renal diseases (palife study)

Conditions: Chronic Kidney Disease, Unspecified

Summary: the purpose of this study is to estimate the differences between albuminuria values determined as urine albumin-to-creatinine ratio (uacr)(log transformed) from baseline to last observation caused by paricalcitol between the group of control and group of treatment.

clinical trial to estimate uacr determined albuminuria differences between treatment and non-treatment groups from basal intake to last study-related observation. patients should suffer proteinuric chronical kidney disease and recovered levels of seric 25(oh)d. also, this clinical trial tries to determinate the effect of paricalcitol over several metabolic and inflammatory parameters on patients.

Eligibility criteria:
inclusion criteria: * informed consent signed * patients will be men or women, between 18 and 75 years old. * patients must have been taken an stable dosis of angiotensine converter enzyme inhibitor, angiotensine receptor antagonism or antialdosterone at last 6 months before screening visit. * patients should not be on dialysis treatment. * women should not be pregnant, or in fertile period (at last 1 year postmenopausal or chirurgic sterilized or using this contraceptive methods: condoms, gel, intrauterine devices, anticonceptives, etc. during at last 3 months after the study beginning. exclusion criteria: * patients have taken active vitamin d during 6 months after the screening. * patients with allergy o sensibility to paricalcitol. * patients with acute ckd 12 weeks before the screening. * patients with chronical gastrointestinal disease. * patients with hypo or hyperthyroidism. * patients with secondary hypertension * bad controled hypertension patients * patients with renal lithiasis * patients with drug dependence * patients taking calcitonins, biphosphonates, cinacalcet or others ca-metabolism drugs. * patients taking immunosuppressor drugs. * patients not adequate to study as medical opinion. * hiv patients * seric p \> 5.0 mg/dl. * seric ca\> 10,0 mg/dl. * proteinuria \> 3.500 mg/g * hypoalbuminemia \< 3g/dl

Keywords: chronic kidney disease proteinuria albuminuria paricalcitol
cemented versus cementless unicompartmental knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: unicompartmental knee replacement for selected cases of osteoarthritis is less invasive than total knee replacement. it gives better range of movement; patients stay for shorter time in the hospital and have a more natural feel than total knee replacement. usually, the implant is fixed in the bone using bone cement. however, there are potential disadvantages of using bone cement. the operation takes longer; cement can get squeezed out into the surrounding tissues and may interfere with function. to avoid these problems, the implant can be fixed without cement. cementless components have a special coating to encourage bone in-growth and fixation. although the investigators believe cementless fixation will be at least as good as cemented fixation, there is a risk that it could be worse and might result in loosening. the aim of this study is therefore to compare the outcome of cemented and cementless unicompartmental knee replacement.

design: a prospective, randomised trial to compare the outcome of cemented and cementless unicompartmental knee replacement. size: 40 subjects in total will be recruited with 20 in each arm. methods: patients will be recruited from the routine waiting list for unicompartmental knee replacement at the nuffield orthopaedic centre. all subjects will have the procedure explained and be fully consented prior to the procedure. randomisation: patients will be randomly allocated to receive either a cemented or cementless oxford unicompartmental knee replacement. this will be performed using a randomisation program based on optimisation (minim). subjects will be stratified according to sex and age. operation: all subjects will undergo the same surgical approach. 0.8mm tantalum marker balls will be placed at standardised sites on the femur and tibia in all cases. all cemented components will be secured using the same cement. cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. follow-up: all patients will be followed up at 0, 3, 6, 12, 24, 60, and 120 months with clinical and radiological assessment. clinical assessment will involve documentation with the oxford knee score. patients will undergo radiostereometric analysis and fluoroscopy to study implant migration and occurence of radiolucency, respectively.

Eligibility criteria:
inclusion criteria: * healthy subjects with osteoarthritis of knee fulfilling the standard indications for an oxford unicompartmental knee replacement. * american society of anaesthesiologists (asa) score of 1 to 3. exclusion criteria: * subjects with severe limiting systemic illness (i.e. asa \> 3). * subjects who are too large for radiostereometric analysis to be carried out. * subjects who have had previous open surgery or anterior cruciate ligament (acl) reconstruction on the same knee.

Keywords: knee arthroplasty unicompartmental fixation radiostereometric analysis
entecavir plus adefovir in lamivudine-resistant patients

Conditions: Hepatitis B, Chronic

Summary: combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in chinese adults with lamivudine-resistant chronic hepatitis b infection


Eligibility criteria:
inclusion criteria: * chb hbeag(+) subject with lamivudine treatment history must have lvdr substitution at rtm204v/i * naïve to nucleoside/nucleotide analogues except for lvd * hbv dna \> 17,200 iu/ml * compensated liver function * serum alt \<10 × uln exclusion criteria: * women who are pregnant or breastfeeding * evidence of decompensated cirrhosis * coinfection with hiv, hepatitis c virus (hcv), or hepatitis d virus (hdv)
peptide vaccination in treating patients with esophageal cancer (stf-ii)

Conditions: Esophageal Cancer

Summary: the purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (stf-ii) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

the phase ii multicenter trial of vaccination study using peptides derived from urlc10, cdca1, and koc1 for locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (escc) who had failed for the standard therapy are performed to evaluate the survival benefit of the cancer vaccination.

Eligibility criteria:
inclusion criteria: disease characteristics 1. locally advanced, recurrent or metastatic esophageal squamous cell carcinoma who had failed for the standard therapy patients characteristics 1. ecog performance status 0-2 2. age≧20 years, 80≦years 3. wbc≥ 2,000/mm³ platelet count ≥ 75,000/mm³ total bilirubin ≤ 2.0 x the institutional normal upper limits ast, alt, alp ≤ 2.5 x the institutional normal upper limits creatinine ≤ 1.5 x the institutional normal upper limits 4. no therapy 4 weeks prior to the initiation of the trial 5. able and willing to give valid written informed consent - exclusion criteria: 1. pregnancy (women of childbearing potential: refusal or inability to use effective means of contraception) 2. breastfeeding 3. serious bleeding disorder 4. serious infections requiring antibiotics 5. concomitant treatment with steroids or immunosuppressing agent 6. decision of unsuitableness by principal investigator or physician-in-charge -

Keywords: epitope peptide, ctl, esophageal cancer, vaccination
lipid-lowering effect and hypotensive effect of shanzha fruit drink in patients

Conditions: Hyperlipidemia; Hypertension

Summary: this is a single-center, randomized, double-blind, placebo-controlled, cross-over study. subjects who meet the inclusion/exclusion criteria will be randomly and alternatively assigned to receive shanzha fruit drink or placebo drink in the first 2 months or the last two months of the 5 months study period. in between the first and second treatment period, all patients will enter a washout period of 4 weeks and during which time patients should not receive any of the study functional fruit drink.


Eligibility criteria:
inclusion criteria: * • total cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l). * mean plasma triglyceride \>= 4.5 mmol/l. * diastolic blood pressure 95-100 mm hg and/or systolic blood pressure 130-150 mm hg. * be able to give written informed consent prior to study start and comply with study requirements. exclusion criteria: * • total cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l). * mean plasma triglyceride \< 4.5 mmol/l. * diastolic blood pressure 95-100 mm hg and/or systolic blood pressure 130-150 mm hg. * be able to give written informed consent prior to study start and comply with study requirements.
mild to moderate acute pancreatitis: early nasogastric tube feeding compared with pancreas rest (mimosa)

Conditions: Acute Pancreatitis

Summary: pain relapse during oral refeeding occurs in at least one-fifth of patients with acute pancreatitis. the study hypothesis is that early administered enteral tube feeding might reduce a risk of pain relapse and shorten the length of hospital stay in patients with acute pancreatitis.


Eligibility criteria:
inclusion criteria: * diagnosis of acute pancreatitis * age 18 years or older * written informed consent exclusion criteria: * \> 96 hours after onset of symptoms * \> 24 hours after hospital admission * organ failure by the time of randomization * infectious complications before randomization * received artificial nutrition before randomization * previously enrolled into the trial * chronic pancreatitis * post-ercp pancreatitis * intraoperative diagnosis of acute pancreatitis * pregnancy * malignancy

Keywords: acute pancreatitis enteral nutrition pancreas rest
histology of functional density in postmenopausal breast

Conditions: Dense Breasts; Breast Cancer

Summary: increased mammographic density is recognized as an important risk factor for developing breast cancer, however, the underlying mechanism explaining this relationship is unclear. the investigators hypothesize that molecular breast imaging (mbi) can more accurately distinguish dense tissue on mammography which is at high risk from dense tissue at low risk by indicating cellular activity in dense tissue as radiotracer uptake (functional density) in the breast. in this pilot study, the investigators want to compare the histological characteristics of breast tissue in patients with who have similar density on mammography but different levels of functional density on mbi.


Eligibility criteria:
inclusion criteria: 1. age 40 or older 2. be postmenopausal as defined as having at least 12 consecutive months of amenorrhea 3. screening mammogram performed at mayo clinic rochester within one year prior to the current mbi study which demonstrates 1. negative or benign assessment (birads category 1-2) 2. no proliferative benign lesions (e.g. fibroadenomas) identified 3. heterogeneously dense or extremely dense parenchyma (birads density category 3 or 4) 4. mbi performed less than one month prior to biopsy demonstrating either significant fd or photopenic fd. exclusion criteria: 1. using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors within six months prior to study biopsy. 2. personal history of any cancer, except non-melanomatous skin cancer 3. current breast symptoms 4. breast implants 5. known allergy to local anesthetic. 6. history of bleeding complications from prior interventions 7. current use of anticoagulants (e.g., coumadin or other blood thinners) 8. major medical condition